Our view, stated clearly.
We see myo-inositol as the foundation of an inositol-centered women's formula. It has the broader research base and should remain the dominant form when paired with D-chiro-inositol.
What makes myo-inositol distinct?
Myo-inositol is the most abundant inositol stereoisomer in human tissues. It contributes to phosphoinositide signaling and serves as a precursor for second messengers used by insulin and other signaling systems. Some myo-inositol is converted into D-chiro-inositol, with tissue-specific ratios reflecting different biological needs.1
This is why “myo-inositol” is more informative than a generic “inositol” label. It identifies the form used in much of the metabolic and reproductive research.
What has human research found?
Multiple randomized trials in women with PCOS have reported changes in insulin measures, androgen measures, or ovulatory outcomes. In one double-blind study of 42 women, myo-inositol plus folic acid was compared with folic acid alone and improvements were reported across selected metabolic and hormonal outcomes.2
Together, these studies support a measured role for myo-inositol in metabolic and reproductive-wellness formulas. The findings apply to the specific formulations, comparators, amounts, diagnostic criteria, and outcomes studied.
What does the amount tell you?
Many published myo-inositol trials used gram-level daily amounts. ESTHELIV Optimal Ovarian Health provides 1,000 mg myo-inositol with 25 mg D-chiro-inositol per daily serving. That preserves a 40:1 relationship, but it should not be described as identical to trials using a different total amount.3
We disclose both the form and amount because ratio alone is not enough: 40:1 describes proportion, not total dose.
Myo-inositol has earned a central—not decorative—role in the formula. We pair it thoughtfully, disclose its amount, and avoid pretending that every gram-level study validates every lower-dose product.
What a responsible formula should disclose
Exact form
“Inositol,” myo-inositol, and D-chiro-inositol are not equally precise label descriptions.
Daily amount
Read the full serving—not a single capsule—and do not confuse a ratio with a dose.
Formula purpose
Each form should have a defined role rather than being added for a front-label claim.
Evidence boundary
PCOS, fertility, and metabolic conditions require individualized medical care.
Myo-Inositol FAQs
Is myo-inositol the same as inositol?+
It is one form of inositol and the form commonly implied by the generic term, but precise labels should still name it when form-specific evidence is being discussed.
Why pair it with D-chiro-inositol?+
The two forms participate in related but distinct insulin-linked signaling pathways. Pairing aims to preserve complementary roles rather than treating them as substitutes.
Is more always better?+
No. Amount, tolerability, formula context, and the evidence for the intended use all matter.
Can it replace medical care for PCOS?+
No. PCOS requires individualized assessment, and inositol should not replace diagnosis, lifestyle care, or prescribed treatment.
References
- 2023 International Evidence-based Guideline for PCOSTeede HJ, et al. Human Reproduction. 2023;38(9):1655–1679.
- Inositol for PCOS: systematic review informing the 2023 guidelineFitz V, et al. Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630–1655.
- Metabolic and hormonal effects of myo-inositol: double-blind trialCostantino D, et al. European Review for Medical and Pharmacological Sciences. 2009;13(2):105–110.
- Comparison of myo-inositol and D-chiro-inositol on ovarian and metabolic factorsPizzo A, et al. Gynecological Endocrinology. 2014;30(3):205–208.